The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
Open accessAbstract
BACKGROUND: Although regulatory T cells (Treg) are highly enriched in human tumours compared with peripheral blood, expression of the immune-checkpoint receptors, immunosuppressive molecules and function of Treg in these two sites remains undefined. METHODS: Tumour-infiltrating lymphocytes and peripheral blood lymphocytes were isolated from a cohort of head and neck squamous cell carcinoma (HNSCC) patients. The immunosuppressive phenotypes and function of intratumoral Treg were compared with those of peripheral blood Treg. RESULTS: The frequency of immune-checkpoint receptor-positive cells was higher on intratumoral FOXP3(+)CD25(hi) Treg compared with circulating Treg (CTLA-4, P=0.002; TIM-3, P=0.002 and PD-1, P=0.002). Immunosuppressive effector molecules, LAP and ectonucleotidase CD39 were also upregulated on intratumoral FOXP3(+) Treg (P=0.002 and P=0.004, respectively). CTLA-4 and CD39 were co-expressed on the majority of intratumoral FOXP3(+)CD4(+) Treg, suggesting that these molecules have a key role in regulatory functions of these cells in situ. Notably, intratumoral Treg exhibited more potently immunosuppressive activity than circulating Treg. CONCLUSION: These results indicate that intratumoral Treg are more immunosuppressive than circulating Treg and CTLA-4 and CD39 expressed can be potential target molecules to inhibit suppressive activities of intratumoral Treg in situ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Coombes, J. L., Siddiqui, K. R. R., Arancibia-Cárcamo, C. V., Hall, J., Sun, C.-M., Belkaid, Y., & Powrie, F. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070590 · Cited by 2,710
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Sun, C.-M., Hall, J. A., Blank, R. B., Bouladoux, N., Oukka, M., Mora, J. R., & Belkaid, Y. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070602 · Cited by 1,881
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
Fife, B. T., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00662.x · Cited by 1,054
Hiraoka, N., Onozato, K., Kosuge, T., & Hirohashi, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0369 · Cited by 831
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3108 · Cited by 786
Ichihara, F., Kono, K., Takahashi, A., Kawaida, H., Sugai, H., & Fujii, H. (2003) · PubMed · Cited by 489
deLeeuw, R. J., Kost, S. E., Kakal, J. A., & Nelson, B. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3216 · Cited by 437
Mandapathil, M., Hilldorfer, B., Szczepanski, M. J., Czystowska, M., Szajnik, M., Ren, J., Lang, S., Jackson, E. K., Gorelik, E., & Whiteside, T. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.047423 · Cited by 390
Self-citationDistinct roles of CTLA‐4 and TGF‐β in CD4+CD25+ regulatory T cell function
Tang, Q., Boden, E. K., Henriksen, K. J., Bour‐Jordan, H., Bi, M., & Bluestone, J. A. (2004) · European Journal of Immunology · doi:10.1002/eji.200425143 · Cited by 377
Camisaschi, C., Casati, C., Rini, F., Perego, M., De Filippo, A., Triebel, F., Parmiani, G., Belli, F., Rivoltini, L., & Castelli, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903879 · Cited by 350
Pietra, G., Manzini, C., Rivara, S., Vitale, M., Cantoni, C., Petretto, A., Balsamo, M., Conte, R., Benelli, R., Minghelli, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2544 · Cited by 324
Strauss, L., Bergmann, C., Gooding, W., Johnson, J. T., & Whiteside, T. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1403 · Cited by 281
Self-citationSchaefer, C., Kim, G. G., Albers, A., Hoermann, K., Myers, E. N., & Whiteside, T. L. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602407 · Cited by 271
Self-citationENTPD1/CD39 is a promising therapeutic target in oncology
Bastid, J., Cottalorda-Regairaz, A., Alberici, G., Bonnefoy, N., Eliaou, J.-F., & Bensussan, A. (2013) · Oncogene · doi:10.1038/onc.2012.269 · Cited by 202
CD39/Adenosine Pathway Is Involved in AIDS Progression
Nikolova, M., Carriere, M., Jenabian, M.-A., Limou, S., Younas, M., Kök, A., Huë, S., Seddiki, N., Hulin, A., Delaneau, O., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002110 · Cited by 177
Darrasse-Jèze, G., Bergot, A., Durgeau, A., Billiard, F., Salomon, B. L., Cohen, J. L., Bellier, B., Podsypanina, K., & Klatzmann, D. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36628 · Cited by 171
TGF-β-Mediated Suppression by CD4+CD25+ T Cells Is Facilitated by CTLA-4 Signaling
Oida, T., Xu, L., Weiner, H. L., Kitani, A., & Strober, W. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2331 · Cited by 133
Immune checkpoints in central nervous system autoimmunity
Joller, N., Peters, A., Anderson, A. C., & Kuchroo, V. K. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01136.x · Cited by 119
Schuler, P. J., Schilling, B., Harasymczuk, M., Hoffmann, T. K., Johnson, J. T., Lang, S., & Whiteside, T. L. (2012) · European Journal of Immunology · doi:10.1002/eji.201142347 · Cited by 114
Self-citationZheng, Y., Manzotti, C. N., Burke, F., Dussably, L., Qureshi, O., Walker, L. S. K., & Sansom, D. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1683 · Cited by 101
Sainz‐Perez, A., Lim, A., Lemercier, B., & Leclerc, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0277 · Cited by 83
Maturation Pathways of Dendritic Cells Determine TAP1 and TAP2 Levels and Cross-presenting Function
López‐Albaitero, A., Mailliard, R. B., Hackman, T., Filho, P. A. A., Wang, X., Gooding, W. E., Ferrone, S., Kaliński, P., & Ferris, R. L. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181a1c24e · Cited by 49
Self-citationPérez, N., Karumuthil‐Melethil, S., Li, R., Prabhakar, B. S., Holterman, M., & Vasu, C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.6566 · Cited by 48
Program death-1 regulates peripheral T cell tolerance via an anergy-independent mechanism
Qiao, G., Yang, L., Li, Z., Ying, H., Hassen, Y., Yin, F., & Zhang, J. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.02.006 · Cited by 13
Cited by
LAG 3 (CD 223) as a cancer immunotherapy target
Andrews, L. P., Marciscano, A. E., Drake, C. G., & Vignali, D. A. A. (2017) · Immunological Reviews · doi:10.1111/imr.12519 · Cited by 956
Tim‐3 and its role in regulating anti‐tumor immunity
Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856
Chaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 511
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
Solomon, B., Young, R. J., & Rischin, D. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.008 · Cited by 467
Metadata
- Authors
- Jie, H.-B., Gildener-Leapman, N., Li, J., Srivastava, R. M., Gibson, S. P., Whiteside, T. L., & Ferris, R. L.
- Venue
- British Journal of Cancer
- Published
- 2013-10-29
- Volume
- 109
- Issue
- 10
- Pages
- 2629-2635
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2057965214
- Cited by
- 286
- References
- 28
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.